UNIGE document Scientific Article
previous document  unige:20035  next document
add to browser collection

Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice

Pierroz, Dominique D.
Rufo, Anna
Glatt, Vaida
Capulli, Mattia
Rucci, Nadia
Cavat, Fanny
show hidden authors show all authors [1 - 11]
Published in Journal of Bone and Mineral Research. 2009, vol. 24, no. 5, p. 775-784
Abstract PTH-stimulated intracellular signaling is regulated by the cytoplasmic adaptor molecule beta-arrestin. We reported that the response of cancellous bone to intermittent PTH is reduced in beta-arrestin2(-/-) mice and suggested that beta-arrestins could influence the bone mineral balance by controlling RANKL and osteoprotegerin (OPG) gene expression. Here, we study the role of beta-arrestin2 on the in vitro development and activity of bone marrow (BM) osteoclasts (OCs) and Ephrins ligand (Efn), and receptor (Eph) mRNA levels in bone in response to PTH and the changes of bone microarchitecture in wildtype (WT) and beta-arrestin2(-/-) mice in models of bone remodeling: a low calcium diet (LoCa) and ovariectomy (OVX). The number of PTH-stimulated OCs was higher in BM cultures from beta-arrestin2(-/-) compared with WT, because of a higher RANKL/OPG mRNA and protein ratio, without directly influencing osteoclast activity. In vivo, high PTH levels induced by LoCa led to greater changes in TRACP5b levels in beta-arrestin2(-/-) compared with WT. LoCa caused a loss of BMD and bone microarchitecture, which was most prominent in beta-arrestin2(-/-). PTH downregulated Efn and Eph genes in beta-arrestin2(-/-), but not WT. After OVX, vertebral trabecular bone volume fraction and trabecular number were lower in beta-arrestin2(-/-) compared with WT. Histomorphometry showed that OC number was higher in OVX-beta-arrestin2(-/-) compared with WT. These results indicate that beta-arrestin2 inhibits osteoclastogenesis in vitro, which resulted in decreased bone resorption in vivo by regulating RANKL/OPG production and ephrins mRNAs. As such, beta-arrestins should be considered an important mechanism for the control of bone remodeling in response to PTH and estrogen deprivation.
Keywords AnimalsArrestins/deficiency/*metabolismBiological Markers/metabolismBone Marrow Cells/drug effects/metabolismBone Remodeling/drug effects/*geneticsBone and Bones/drug effects/metabolism/pathologyCalcium, Dietary/administration & dosage/pharmacologyCells, CulturedCoculture TechniquesEphrins/*genetics/metabolism*Gene Expression Regulation/drug effectsGene Silencing/drug effectsMiceOrgan Size/drug effectsOsteoblasts/drug effects/metabolismOsteoclasts/drug effects/metabolismOsteogenesis/drug effectsOvariectomyParathyroid Hormone/pharmacologyRANK Ligand/*genetics/metabolismReceptors, Eph Family/*genetics/metabolism
PMID: 19113915
Full text
Research groups Génétique des Ostéoporoses (544)
Nutrition et os (66)
(ISO format)
PIERROZ, Dominique D. et al. Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice. In: Journal of Bone and Mineral Research, 2009, vol. 24, n° 5, p. 775-784. doi: 10.1359/jbmr.081237 https://archive-ouverte.unige.ch/unige:20035

392 hits

0 download


Deposited on : 2012-04-23

Export document
Format :
Citation style :